Open access peer-reviewed Edited Volume

Kidney Cancer

Jindong Chen

University of Rochester

Prof. Chen earned his PhD in Karolinska Institute, Sweden. He served as Research Scientist at Van Andel Research Institute, USA; Senior Scientist at National Cancer Centre Singapore and NUS-Duke University Graduate School. He identified two cancer-related genes, NORE1 and LSAMP by positional cloning strategy, and was awarded in the 94th and in the 100th AACR annual meeting.


Kidney Carcinoma Kidney Neoplasm Cancer Chemotherapy Immunotherapy Target Therapy Robot Surgery Biomarkers Combination Strategies Transplantation Metastasis Treatment Renal Cell Carcinoma

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Systemic therapy for advanced kidney cancer or metastatic renal cell carcinoma has greatly evolved over the last decade. The treatment landscape for advanced kidney cancer has evolved since the introduction of VEGF inhibitors. Currently, therapies for metastatic renal cell carcinoma include mammalian target of rapamycin (mTOR) inhibitors, new multikinase inhibitors (Cabozantinib, Lenvatinib, Tivozanib), vascular endothelial growth factor (VEGF)-directed therapy, cytokines, vaccines, and immune checkpoint inhibitors (ICIs) (e.g. Nivolumab, Opdivo®). VEGF tyrosine kinase inhibitor monotherapy had been the standard therapy, and its use is evolving in the front-line setting with ICIs; cabozantinib provides superior progression-free survival versus sunitinib in intermediate- and poor-risk patients, by International Metastatic RCC Database Consortium criteria.

Recently, combination strategies involving contemporary immunotherapy have emerged as key opportunities to further shift the treatment landscape. Numerous combinations with PD-1/PD-L1 inhibitors are compared to Sunitinib as the first-line treatment of mRCC. Thus, combination therapies involving ICIs could be the next standard of care and management in kidney cancer. With the expanding application of ICIs in advanced kidney cancer, the bar has been raised in evaluating ongoing combination strategies in this field. In this book, we will introduce and discuss a variety of systemic therapies including clinical trials adopted in advanced kidney cancer.

Publishing process

Book initiated and editor appointed

Date completed: August 27th 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: November 23rd 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: February 11th 2021

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: April 12th 2021

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Jindong Chen

University of Rochester

Jindong Chen, Ph.D., AACR active member, Research Associate Professor, Laboratory Co-director, Department of Urology, University of Rochester Medical Center, New York, USA. He earned his Ph.D. in Karolinska Institute, Sweden. Then, he served as Research Scientist at Van Andel Research Institute, USA; Senior Scientist at National Cancer Centre Singapore and NUS-Duke University Graduate School. He has worked on colorectal carcinoma, breast cancer, and kidney cancer for more than 20 years. He identified two cancer-related genes, NORE1 and LSAMP by positional cloning strategy, and was awarded in the 94th AACR annual meeting. Afterward, he has successfully developed several FLCN and HRPT2 conditional knockout mouse models and was again awarded in the 100th AACR annual Meeting for generating a tumor-developing FLCN knockout mouse model. By using those mouse models, he has conducted quite a few anti-cancer drug tests.

View profile

Book chapters authored 0

Books edited 2

Introducing your Author Service Manager

Mr. Josip Knapic

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copy-editing and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in